Compare NTB & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | HRMY |
|---|---|---|
| Founded | 1858 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2016 | 2020 |
| Metric | NTB | HRMY |
|---|---|---|
| Price | $58.84 | $39.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $65.33 | $47.64 |
| AVG Volume (30 Days) | 128.6K | ★ 875.3K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $5.45 | $18.74 |
| Revenue Next Year | $87.38 | $12.98 |
| P/E Ratio | ★ $9.64 | $21.66 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $40.59 | $25.52 |
| 52 Week High | $64.17 | $43.49 |
| Indicator | NTB | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 43.26 |
| Support Level | $57.98 | $34.87 |
| Resistance Level | $61.42 | $43.38 |
| Average True Range (ATR) | 0.98 | 1.32 |
| MACD | -0.01 | -0.38 |
| Stochastic Oscillator | 61.98 | 11.24 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It offers banking services, comprising retail and corporate banking, and wealth management services, which consist of trust, private banking, and asset management business. The company operates through four reportable segments: Bermuda, Cayman, Channel Islands and the UK, and Other. In its Bermuda and Cayman segments, the company offers retail banking and wealth management services. In the Channel Islands and the UK segment, the company offers retail and corporate banking and wealth management services, and the Other segment includes its operations in the Bahamas, Canada, Mauritius, Singapore, and Switzerland. Maximum revenue for the company is generated from its business in Bermuda.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.